SB2, Inc.
Records under this name other than the patents SB2, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,124,106 | Method for detecting cancers Formerly held Term ended Term ended Mar 10, 2019 · From the USPTO record | Term ended | Term ended Mar 10, 2019 | From the USPTO record |
| US 6,217,868 | Methods for detecting cancer cells by using humanized antibodies which bind specifically to FB5 antigen Formerly held Term ended Term ended Nov 2, 2018 · From the USPTO record | Term ended | Term ended Nov 2, 2018 | From the USPTO record |
| US 6,310,185 | Recombinant human anti-Lewis Y antibodies Formerly held Term ended Term ended Oct 30, 2018 · From the USPTO record | Term ended | Term ended Oct 30, 2018 | From the USPTO record |
| US 6,090,930 | Recombinant human anti-FB5 antibodies Formerly held Term ended Term ended Jan 27, 2018 · From the USPTO record | Term ended | Term ended Jan 27, 2018 | From the USPTO record |
| US 6,348,195 | Method for treating cancers Formerly held Term ended Term ended Mar 8, 2014 · From the USPTO record | Term ended | Term ended Mar 8, 2014 | From the USPTO record |
| US 6,391,302 | Method for treating cancers which present antigen FB5 with humanized antibodies Formerly held Term ended Term ended Mar 8, 2014 · From the USPTO record | Term ended | Term ended Mar 8, 2014 | From the USPTO record |
| US 6,518,415 | Recombinant human anti-Lewis Y antibodies Formerly held Term ended Term ended Mar 8, 2014 · From the USPTO record | Term ended | Term ended Mar 8, 2014 | From the USPTO record |
| US 6,025,477 | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof Lapsed on the fee record Ended Feb 15, 2012 · From the USPTO record | Lapsed on the fee record | Ended Feb 15, 2012 | From the USPTO record |
| US 5,624,821 | Antibodies with altered effector functions Term ended Term ended no later than Apr 29, 2017 · Low confidence | Term ended | Term ended no later than Apr 29, 2017 | Low confidence |
| US 5,646,253 | Recombinant human anti-LK26 antibodies Formerly held Term ended Term ended no later than Jul 8, 2017 · Low confidence | Term ended | Term ended no later than Jul 8, 2017 | Low confidence |